Cartesian (RNAC) Q2 Revenue Drops 99%

Cartesian Therapeutics (NASDAQ:RNAC), a biotechnology company pioneering mRNA cell therapies for autoimmune diseases, The company released its Q2 2025 earnings on August 7, 2025. In the update, the company posted a headline net income result far above expectations, with GAAP earnings per share at $0.51 compared to an estimated ($0.80) loss. This steep decline in GAAP collaboration and license revenue highlights the absence of last year's sizable collaboration and license payments. The operational picture remained challenging, with ongoing investment in key clinical trials and elevated research expenses. The launch of the Phase 3 AURORA trial for Descartes-08 in myasthenia gravis was a major operational milestone, but the quarter reinforced both the advances and the risks facing the company as it works toward late-stage development and eventual commercialization. Source: Analyst estimates for the quarter provided by FactSet. Cartesian Therapeutics is a biotech specializing in mRNA cell therapies, with a focus on treating severe autoimmune diseases. It leverages messenger RNA (mRNA) technology, which avoids permanent changes to a patient's genetic material and allows therapies to be dosed multiple times without pre-treatment chemotherapy.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool